We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for streaming realtime charts, analysis tools, and prices.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Mylan NV | NASDAQ:MYL | NASDAQ | Common Stock |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 15.855 | 15.71 | 15.90 | 0 | 01:00:00 |
From Jun 2019 to Jun 2024
DOW JONES NEWSWIRES
Mylan Inc. (MYL) said the U.S. Food and Drug Administration found no deficiencies in a Morgantown, W.Va., plant that had been the subject of media reports that questioned its quality control.
Last month, the Pittsburgh Post-Gazette reported that generic-drug maker Mylan had launched an internal probe to investigate whether workers at the plant had been routinely overriding computer-generated warnings about the drugs being produced at the plant. The newspaper cited an internal report and had other experts review the report and call it a significant problem.
Chief Executive Robert Coury has blasted the reporting in the article and said it contained allegations that were "false, misleading and unfounded."
"The baseless speculation that was caused by a highly irresponsible and sensational news article with a biased agenda was entirely unnecessary," Coury said Thursday.
Mylan's shares were up 3.5% at $14.07.
- By Kerry Grace Benn, Dow Jones Newswires; 212-416-2353; kerry.benn@dowjones.com
1 Year Mylan NV Chart |
1 Month Mylan NV Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
